InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,200.40
(
-0.33%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.90
(
-0.61%
)
Bitcoin
60,117.44
(
-2.43%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119954
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 106451

Tuesday, 10/19/2010 9:36:49 PM

Tuesday, October 19, 2010 9:36:49 PM

Post# of 252426
More from GILD’s 3Q10 CC: The European MAA for ‘Btripla’ (the combination pill consisting of JNJ’s TMC278 and Truvada) was submitted on 9/3/10; with a typical review period, a decision will come in 4Q11. (The EMA does not have the equivalent of an FDA priority review for drugs that meet an unmet medical need.)

The Btripla NDA submission to the FDA is planned for Nov 2010; with a priority review, the FDA decision will come in 2Q11.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up